EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Efficacy and safety of nilotinib in steroid-refractory chronic graft-versus-host disease: A systematic review and meta-analysis

Eshak I Bahbah, Mahmoud Ali, Osama Elshabasy, Mahmoud Attia

Transplant Immunology · 2026-08 · 97 · 102415

DOI: 10.1016/j.trim.2026.102415 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Transplant Immunology, 2026-08. Verfasst von Eshak I Bahbah und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Al-Azhar University, New Damietta, Egypt; Real-World Evidence Department, MedDots, Sharjah, United Arab Emirates. Electronic add…. Hauptthemen laut MEDLINE: Graft vs Host Disease, Pyrimidines, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: This systematic review and meta-analysis evaluated the efficacy and safety of nilotinib in patients with steroid-refractory or steroid-dependent chronic graft-versus-host disease (SR/D cGVHD). METHODS: Electronic databases and trial registries were searched from inception to June 2025. Study selection, data extraction, risk-of-bias assessment, and GRADE evaluation were performed independently. Proportions were pooled using random-effects meta-analysis. RESULTS: Four prospective single-arm early-phase interventional studies (n = 112 patients) were included. The pooled overall response rate (ORR) was 36% (95% CI: 13% to 59%; I2 = 84.9%), but the estimate was strongly influenced by the sequential rituximab-nilotinib study by van der Wagen et al.; after omission of this study, ORR decreased to 24% (95% CI: 13% to 34%; I2 = 0%). Complete and partial response rates were 8% (95% CI: 2% to 14%) and 32% (95% CI: 10% to 54%), respectively. Treatment discontinuation due to adverse events occurred in 26% (95% CI: 9% to 43%; I2 = 82.5%). The certainty of evidence was very low for most outcomes. CONCLUSION: Nilotinib was associated with modest and heterogeneous efficacy in SR/D cGVHD. The available evidence does not support routine salvage use after imatinib failure or intolerance; any future role is likely to be restricted to carefully selected patients, preferably within biomarker-guided or dose-optimized protocols.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseasePyrimidinesHematopoietic Stem Cell TransplantationHumansChronic DiseaseSteroidsTreatment OutcomeDrug Resistance

Stichwörter der Autor:innen

Chronic graft-versus-host diseaseMeta-analysisNilotinibSteroid-refractoryTyrosine kinase inhibitorscGVHD

Substanzen

nilotinibPyrimidinesSteroids

Autor:innen und Institutionen

  • Faculty of Medicine, Al-Azhar University, New Damietta, Egypt; Real-World Evidence Department, MedDots, Sharjah, United Arab Emirates. Electronic address: isaacbahbah@gmail.com.
  • Faculty of Medicine, Al-Azhar University, New Damietta, Egypt.
  • Yeovil District Hospital NHS Foundation Trust, Yeovil, UK; Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK.

Zitieren

APA

Bahbah, E. I., Ali, M., Elshabasy, O., & Attia, M. (2026). Efficacy and safety of nilotinib in steroid-refractory chronic graft-versus-host disease: A systematic review and meta-analysis. Transplant Immunology, 97, 102415. https://doi.org/10.1016/j.trim.2026.102415

Vancouver

Bahbah EI, Ali M, Elshabasy O, Attia M. Efficacy and safety of nilotinib in steroid-refractory chronic graft-versus-host disease: A systematic review and meta-analysis. Transplant Immunology. 2026;97:102415. doi:10.1016/j.trim.2026.102415

BibTeX
@article{Bahbah2026,
  author = {Bahbah, Eshak I and Ali, Mahmoud and Elshabasy, Osama and Attia, Mahmoud},
  title = {Efficacy and safety of nilotinib in steroid-refractory chronic graft-versus-host disease: A systematic review and meta-analysis},
  journal = {Transplant Immunology},
  year = {2026},
  volume = {97},
  pages = {102415},
  doi = {10.1016/j.trim.2026.102415}
}
Kostenlos starten →